A 24-month, Prospective, Non-interventional Study to Describe the Long Term, Real-Life Use of BOTOX for the symptomatic treatment of Adults with Chronic Migraine, Measuring Healthcare Resource Utilization, and Patient Reported Outcomes Observed in Practice.
Phase of Trial: Phase IV
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms REPOSE
- Sponsors Allergan
- 27 Jun 2017 Results of REPOSE study presented at the 3rd Congress of the European Academy of Neurology.
- 12 Dec 2016 Status changed from active, no longer recruiting to completed.
- 25 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.